Three panel members resigned in protest, including Dr. Aaron Kesselheim, a Harvard Medical School professor, who wrote in his resignation letter that it "was probably the worst drug approval decision in recent U.S. history." In his letters, Carome cites a number of "troubling revelations" from STAT 's reporting that show "unprecedented and inappropriately close collaboration" between FDA officials and Biogen, which is marketing the drug under the brand name Aduhelm. One example is a May 2019 "off the books" meeting between Biogen chief scientist Al Sandrock and Dunn, whom STAT described as the FDA's "top regulator of Alzheimer's drugs," because Sandrock "wanted to know if Dunn would be open to helping find a way to get the drug approved." "It was clear that Billy Dunn was an ally, so the job for Biogen became figuring out how to support his efforts within the FDA," said a former Biogen employee who spoke with STAT.